VX A001
Alternative Names: VX-A001Latest Information Update: 12 Jan 2024
At a glance
- Originator VERAXA Biotech
- Developer Quadira Biosciences; VERAXA Biotech
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Research Solid tumours